Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2013, Article ID 176418, 12 pages
Review Article

Management of Adenovirus in Children after Allogeneic Hematopoietic Stem Cell Transplantation

1Molecular Immunology Unit, UCL Institute of Child Health, 30 Guildford Street, London WC1N 1EH, UK
2Department of Clinical Immunology, Great Ormond Street Hospital, London WC1N 3JH, UK

Received 26 July 2013; Accepted 6 September 2013

Academic Editor: Mark R. Litzow

Copyright © 2013 Winnie WY Ip and Waseem Qasim. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Adenovirus (ADV) can cause significant morbidity and mortality in children following haematopoietic stem cell transplantation (HSCT), with an incidence of up to 27% and notable associated morbidity and mortality. T-cell depleted grafts and severe lymphopenia are major risk factors for the development of adenovirus disease after HSCT. Current antiviral treatments are at best virostatic and may have significant side effects. Adoptive transfer of donor-derived virus-specific T cells has been shown to be an effective strategy for the prevention and treatment of ADV infection after HSCT. Here we review progress in the field and present a pathway for the management of adenovirus in the posttransplant setting.